EUVIMEDEUVIMED entdecken
Crossref

Clinical Outcomes of Low‐Grade Cytomegalovirus DNAemia in Hematopoietic Stem Cell Transplantation Recipients Receiving Letermovir Prophylaxis

Jung Soo Son iD, Eun-Jeong Jeong iD, Hyeon Jae Jo iD, Chan Mi Lee iD, Ja Min Byun iD, Chang Kyung Kang iD, Youngil Koh iD, Junshik Hong iD, Dong-Yeop Shin iD, Pyeong Gyun Choe iD, Wan Beom Park iD, Nam Joong Kim iD und 2 weitere

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70736 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Jung Soo Son und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Antiviral Agents, DNA, Viral. Die Arbeit nennt 57 Literaturangaben. Gefördert von: This study was supported by the SNUH research fund (grant no 0420240250)., Seoul National University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytomegalovirus (CMV) infection remains a major contributor to CMV‐related and hematologic adverse outcomes in hematopoietic stem cell transplantation (HSCT) recipients. While letermovir has improved CMV prophylaxis strategies in this population, the clinical implications of low‐grade CMV DNAemia during letermovir prophylaxis remain uncertain. We retrospectively analyzed 255 HSCT recipients who received letermovir at a tertiary hospital in Korea. Patients were stratified into three groups based on the highest CMV DNAemia levels observed during letermovir prophylaxis: no DNAemia ( n = 72), low‐grade DNAemia (< 1000 IU/mL; n = 171), and high‐grade DNAemia (≥ 1000 IU/mL; n = 12). The association between low‐grade CMV DNAemia and clinical outcomes was assessed using a multivariate Cox proportional hazards model. Most low‐grade DNAemia cases were transient and resolved without antiviral therapy. Compared to no DNAemia, low‐grade CMV DNAemia was not associated with an increased risk of clinically significant CMV infection by Day 100 ( p = 0.262) or Day 365 ( p = 0.399). No significant associations were observed with engraftment failure ( p = 0.098), disease relapse ( p = 0.165), or all‐cause mortality ( p = 0.537). Our findings suggest that close monitoring may be sufficient for low‐grade DNAemia under letermovir prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsHematopoietic Stem Cell TransplantationAntiviral AgentsDNA, ViralAcetatesCytomegalovirusQuinazolinesViremiaHumansMaleFemaleRetrospective StudiesMiddle AgedAdultRepublic of KoreaTreatment OutcomeYoung AdultTransplant RecipientsAgedAdolescentTertiary Care Centers

Stichwörter der Autor:innen

clinical outcomescytomegalovirushematopoietic stem cell transplantationletermovirlow‐grade DNAemia

Substanzen

letermovirAntiviral AgentsDNA, ViralAcetatesQuinazolines

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Jung Soo Son, Eun-Jeong Jeong, Hyeon Jae Jo, Chan Mi Lee, Ja Min Byun, Chang Kyung Kang, Youngil Koh, Junshik Hong, Dong-Yeop Shin, Pyeong Gyun Choe, Wan Beom Park, Nam Joong Kim, Sung-Soo Yoon, Inho Kim

Förderung

  • This study was supported by the SNUH research fund (grant no 0420240250).
  • Seoul National University Hospital

Zitieren

APA

Son, J. S., Jeong, E. J., Jo, H. J., Lee, C. M., Byun, J. M., Kang, C. K., Koh, Y., Hong, J., Shin, D. Y., Choe, P. G., Park, W. B., Kim, N. J., Yoon, S. S., & Kim, I. (2025). Clinical Outcomes of Low‐Grade Cytomegalovirus DNAemia in Hematopoietic Stem Cell Transplantation Recipients Receiving Letermovir Prophylaxis. Journal of Medical Virology. https://doi.org/10.1002/jmv.70736

Vancouver

Son JS, Jeong EJ, Jo HJ, Lee CM, Byun JM, Kang CK, et al. Clinical Outcomes of Low‐Grade Cytomegalovirus DNAemia in Hematopoietic Stem Cell Transplantation Recipients Receiving Letermovir Prophylaxis. Journal of Medical Virology. 2025. doi:10.1002/jmv.70736

BibTeX
@article{Son2025,
  author = {Son, Jung Soo and Jeong, Eun-Jeong and Jo, Hyeon Jae and Lee, Chan Mi and Byun, Ja Min and Kang, Chang Kyung and Koh, Youngil and Hong, Junshik and Shin, Dong-Yeop and Choe, Pyeong Gyun and Park, Wan Beom and Kim, Nam Joong and Yoon, Sung-Soo and Kim, Inho},
  title = {Clinical Outcomes of Low‐Grade Cytomegalovirus DNAemia in Hematopoietic Stem Cell Transplantation Recipients Receiving Letermovir Prophylaxis},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70736}
}
Kostenlos starten →